Sign in

You're signed outSign in or to get full access.

Mal Ramesh

Vice President and Equity Research Analyst at Sudetsky

Mal Ramesh is a Vice President and Equity Research Analyst at Sudetsky, specializing in healthcare and biotechnology sectors with a focus on mid-cap pharmaceutical and life sciences companies. He covers firms such as BioMarin Pharmaceutical, Alnylam Pharmaceuticals, and Vertex Pharmaceuticals, earning recognition for a success rate of 65% and an average annualized return of 13% on his published investment theses. Ramesh began his finance career in 2013 at Cowen Group as a healthcare associate, later advancing to Evercore ISI and joining Sudetsky in 2021. He holds FINRA Series 7 and 63 licenses and has been highlighted by industry platforms for comprehensive pipeline analysis and accurate earnings forecasts.

Mal Ramesh's questions to Yatra Online (YTRA) leadership

Question · Q1 2026

Mal Ramesh from Sudetsky questioned Yatra's 9% gross booking growth relative to the market's double-digit expansion, asking about market share dynamics in air versus hotels. He also inquired about the current business mix and potential cost savings from the corporate restructuring.

Answer

Co-Founder & CEO Dhruv Shringi explained that the blended growth rate was affected by a marginal decline in the consumer business due to macro events, while the corporate segment grew strongly. He confirmed the business mix remains roughly two-thirds corporate and one-third consumer. Shringi also noted the corporate restructuring is expected to yield significant savings, including about $5 million annually in tax savings in India.

Ask follow-up questions

Fintool

Fintool can predict Yatra Online logo YTRA's earnings beat/miss a week before the call

Question · Q1 2026

Mal Ramesh from Sudetsky questioned the company's 9% gross booking growth relative to the market, the current business mix between corporate and consumer travel, and the potential cost savings from the ongoing corporate restructuring.

Answer

Co-Founder & CEO Dhruv Shringi explained that the modest booking growth was a weighted average, with strong corporate performance offset by a macro-impacted decline in the consumer segment. He confirmed the business mix remains roughly two-thirds corporate. Shringi also stated the restructuring will yield savings, including an estimated $5 million in annual tax savings.

Ask follow-up questions

Fintool

Fintool can write a report on Yatra Online logo YTRA's next earnings in your company's style and formatting